Annual EBITDA
-$25.13 M
+$9.63 M+27.70%
31 December 2023
Summary:
Panbela Therapeutics annual earnings before interest, taxes, depreciation & amortization is currently -$25.13 million, with the most recent change of +$9.63 million (+27.70%) on 31 December 2023. During the last 3 years, it has fallen by -$14.52 million (-136.85%). PBLA annual EBITDA is now -8784.17% below its all-time high of $289.40 thousand, reached on 31 December 2012.PBLA EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly EBITDA
-$6.73 M
+$350.00 K+4.94%
30 September 2024
Summary:
Panbela Therapeutics quarterly earnings before interest, taxes, depreciation & amortization is currently -$6.73 million, with the most recent change of +$350.00 thousand (+4.94%) on 30 September 2024. Over the past year, it has dropped by -$309.00 thousand (-4.81%). PBLA quarterly EBITDA is now -5403.39% below its all-time high of $126.90 thousand, reached on 31 December 2012.PBLA Quarterly EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM EBITDA
-$27.43 M
+$1.05 M+3.68%
30 September 2024
Summary:
Panbela Therapeutics TTM earnings before interest, taxes, depreciation & amortization is currently -$27.43 million, with the most recent change of +$1.05 million (+3.68%) on 30 September 2024. Over the past year, it has dropped by -$2.31 million (-9.18%). PBLA TTM EBITDA is now -9576.85% below its all-time high of $289.40 thousand, reached on 31 December 2012.PBLA TTM EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
PBLA EBITDA Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | - | -4.8% | -9.2% |
| 3 y3 years | -136.8% | -103.8% | -159.0% |
| 5 y5 years | -468.5% | -540.3% | -520.5% |
PBLA EBITDA High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | -136.8% | +27.7% | -103.8% | +69.6% | -159.0% | +24.0% |
| 5 y | 5 years | -468.5% | +27.7% | -1379.1% | +69.6% | -520.5% | +24.0% |
| alltime | all time | -8784.2% | +27.7% | -5403.4% | +69.6% | -9576.9% | +24.0% |
Panbela Therapeutics EBITDA History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2024 | - | -$6.73 M(-4.9%) | -$27.43 M(-3.7%) |
| June 2024 | - | -$7.08 M(-1.6%) | -$28.48 M(+4.3%) |
| Mar 2024 | - | -$7.20 M(+12.1%) | -$27.30 M(+8.7%) |
| Dec 2023 | -$25.13 M(-27.7%) | -$6.42 M(-17.5%) | -$25.12 M(+8.0%) |
| Sept 2023 | - | -$7.78 M(+31.6%) | -$23.27 M(+17.2%) |
| June 2023 | - | -$5.91 M(+17.9%) | -$19.86 M(-45.0%) |
| Mar 2023 | - | -$5.01 M(+9.7%) | -$36.08 M(+3.8%) |
| Dec 2022 | -$34.76 M(+227.6%) | -$4.57 M(+4.5%) | -$34.76 M(+3.8%) |
| Sept 2022 | - | -$4.37 M(-80.3%) | -$33.50 M(+5.8%) |
| June 2022 | - | -$22.13 M(+499.5%) | -$31.67 M(+165.9%) |
| Mar 2022 | - | -$3.69 M(+11.8%) | -$11.91 M(+12.5%) |
| Dec 2021 | -$10.61 M(+110.3%) | -$3.30 M(+29.8%) | -$10.59 M(+28.6%) |
| Sept 2021 | - | -$2.54 M(+7.2%) | -$8.24 M(+10.6%) |
| June 2021 | - | -$2.37 M(+0.2%) | -$7.45 M(+34.7%) |
| Mar 2021 | - | -$2.37 M(+150.0%) | -$5.53 M(+9.6%) |
| Dec 2020 | -$5.05 M(+14.1%) | -$948.00 K(-46.0%) | -$5.05 M(-2.0%) |
| Sept 2020 | - | -$1.76 M(+286.2%) | -$5.15 M(+4.0%) |
| June 2020 | - | -$455.00 K(-75.9%) | -$4.95 M(-12.9%) |
| Mar 2020 | - | -$1.89 M(+79.4%) | -$5.69 M(+28.7%) |
| Dec 2019 | -$4.42 M(+1.7%) | -$1.05 M(-32.7%) | -$4.42 M(+6.5%) |
| Sept 2019 | - | -$1.56 M(+31.3%) | -$4.15 M(+16.4%) |
| June 2019 | - | -$1.19 M(+92.1%) | -$3.56 M(-2.4%) |
| Mar 2019 | - | -$619.00 K(-20.6%) | -$3.65 M(-15.9%) |
| Dec 2018 | -$4.34 M | -$780.00 K(-20.2%) | -$4.34 M(-18.5%) |
| Sept 2018 | - | -$977.00 K(-23.4%) | -$5.33 M(+0.7%) |
| June 2018 | - | -$1.28 M(-2.4%) | -$5.29 M(+4.4%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Mar 2018 | - | -$1.31 M(-25.9%) | -$5.07 M(-45.4%) |
| Dec 2017 | -$9.29 M(+76.2%) | -$1.76 M(+87.4%) | -$9.29 M(-5.3%) |
| Sept 2017 | - | -$942.00 K(-10.5%) | -$9.80 M(-1.4%) |
| June 2017 | - | -$1.05 M(-80.9%) | -$9.94 M(+0.3%) |
| Mar 2017 | - | -$5.53 M(+142.2%) | -$9.91 M(+87.8%) |
| Dec 2016 | -$5.27 M(-4.1%) | -$2.28 M(+111.5%) | -$5.28 M(+22.9%) |
| Sept 2016 | - | -$1.08 M(+5.5%) | -$4.30 M(+7.5%) |
| June 2016 | - | -$1.02 M(+14.4%) | -$4.00 M(-4.4%) |
| Mar 2016 | - | -$894.00 K(-31.2%) | -$4.18 M(-23.8%) |
| Dec 2015 | -$5.50 M(+59.2%) | -$1.30 M(+67.1%) | -$5.49 M(+6.8%) |
| Sept 2015 | - | -$778.00 K(-35.5%) | -$5.14 M(-6.0%) |
| June 2015 | - | -$1.21 M(-45.2%) | -$5.47 M(+27.0%) |
| Mar 2015 | - | -$2.20 M(+131.2%) | -$4.31 M(+95.4%) |
| Dec 2014 | -$3.46 M(+1967.6%) | -$952.00 K(-14.0%) | -$2.20 M(+74.9%) |
| Sept 2014 | - | -$1.11 M(+2306.5%) | -$1.26 M(+528.7%) |
| June 2014 | - | -$46.00 K(-53.5%) | -$200.50 K(+4.3%) |
| Mar 2014 | - | -$99.00 K(+1064.7%) | -$192.20 K(+19.3%) |
| Dec 2013 | -$167.10 K(-157.7%) | -$8500.00(-81.9%) | -$161.10 K(+526.8%) |
| Sept 2013 | - | -$47.00 K(+24.7%) | -$25.70 K(-124.4%) |
| June 2013 | - | -$37.70 K(-44.5%) | $105.30 K(-57.1%) |
| Mar 2013 | - | -$67.90 K(-153.5%) | $245.40 K(-15.2%) |
| Dec 2012 | $289.40 K(-387.1%) | $126.90 K(+51.1%) | $289.40 K(+78.1%) |
| Sept 2012 | - | $84.00 K(-18.0%) | $162.50 K(+107.0%) |
| June 2012 | - | $102.40 K(-528.5%) | $78.50 K(-428.5%) |
| Mar 2012 | - | -$23.90 K | -$23.90 K |
| Dec 2011 | -$100.80 K | - | - |
FAQ
- What is Panbela Therapeutics annual earnings before interest, taxes, depreciation & amortization?
- What is the all time high annual EBITDA for Panbela Therapeutics?
- What is Panbela Therapeutics quarterly earnings before interest, taxes, depreciation & amortization?
- What is the all time high quarterly EBITDA for Panbela Therapeutics?
- What is Panbela Therapeutics quarterly EBITDA year-on-year change?
- What is Panbela Therapeutics TTM earnings before interest, taxes, depreciation & amortization?
- What is the all time high TTM EBITDA for Panbela Therapeutics?
- What is Panbela Therapeutics TTM EBITDA year-on-year change?
What is Panbela Therapeutics annual earnings before interest, taxes, depreciation & amortization?
The current annual EBITDA of PBLA is -$25.13 M
What is the all time high annual EBITDA for Panbela Therapeutics?
Panbela Therapeutics all-time high annual earnings before interest, taxes, depreciation & amortization is $289.40 K
What is Panbela Therapeutics quarterly earnings before interest, taxes, depreciation & amortization?
The current quarterly EBITDA of PBLA is -$6.73 M
What is the all time high quarterly EBITDA for Panbela Therapeutics?
Panbela Therapeutics all-time high quarterly earnings before interest, taxes, depreciation & amortization is $126.90 K
What is Panbela Therapeutics quarterly EBITDA year-on-year change?
Over the past year, PBLA quarterly earnings before interest, taxes, depreciation & amortization has changed by -$309.00 K (-4.81%)
What is Panbela Therapeutics TTM earnings before interest, taxes, depreciation & amortization?
The current TTM EBITDA of PBLA is -$27.43 M
What is the all time high TTM EBITDA for Panbela Therapeutics?
Panbela Therapeutics all-time high TTM earnings before interest, taxes, depreciation & amortization is $289.40 K
What is Panbela Therapeutics TTM EBITDA year-on-year change?
Over the past year, PBLA TTM earnings before interest, taxes, depreciation & amortization has changed by -$2.31 M (-9.18%)